Carl June was awarded for his work with chimeric antigen receptor (CAR) T-cell therapy, the first U.S. FDA-approved personalized cellular therapy for cancer.
Carl June Abramson Cancer Center Kymriah Flash Mob.jpg
Carl June was awarded for his work with chimeric antigen receptor (CAR) T-cell therapy, the first U.S. FDA-approved personalized cellular therapy for cancer. Courtesy of Penn Medicine
